{"protocolSection": {"identificationModule": {"nctId": "NCT03193801", "orgStudyIdInfo": {"id": "2015-08 MVIV"}, "organization": {"fullName": "Edwards Lifesciences", "class": "INDUSTRY"}, "briefTitle": "PARTNER 3 Trial - Mitral Valve in Valve", "officialTitle": "PARTNER 3 Trial - SAPIEN 3 Transcatheter Heart Valve Implantation in Patients With a Failing Mitral Bioprosthetic Valve"}, "statusModule": {"statusVerifiedDate": "2023-09", "overallStatus": "ACTIVE_NOT_RECRUITING", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-02-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2022-08-16", "type": "ACTUAL"}, "completionDateStruct": {"date": "2031-08", "type": "ESTIMATED"}, "studyFirstSubmitDate": "2017-06-19", "studyFirstSubmitQcDate": "2017-06-19", "studyFirstPostDateStruct": {"date": "2017-06-21", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-08-15", "resultsFirstSubmitQcDate": "2023-09-29", "resultsFirstPostDateStruct": {"date": "2023-10-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-09-29", "lastUpdatePostDateStruct": {"date": "2023-10-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Edwards Lifesciences", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": true}, "descriptionModule": {"briefSummary": "To assess the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with a failing mitral bioprosthetic valve.", "detailedDescription": "A prospective, single-arm, multicenter clinical trial. This study will enroll patients with symptomatic heart disease due to a failing bioprosthetic mitral valve (stenosed, insufficient, or combined)."}, "conditionsModule": {"conditions": ["Mitral Valve Insufficiency", "Mitral Valve Disease", "Mitral Valve Regurgitation", "Heart Failure"], "keywords": ["SAPIEN 3", "PARTNER 3", "cardiovascular disease", "TMVR", "failing valve", "failing bioprosthetic valve"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 53, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Failing mitral transcatheter valve", "type": "EXPERIMENTAL", "description": "Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.", "interventionNames": ["Device: Edwards SAPIEN 3 transcatheter valve, Model 9600TFX"]}], "interventions": [{"type": "DEVICE", "name": "Edwards SAPIEN 3 transcatheter valve, Model 9600TFX", "description": "Edwards SAPIEN 3 THV system Model 9600TFX with the associated delivery systems.", "armGroupLabels": ["Failing mitral transcatheter valve"], "otherNames": ["TMVR"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Safety and Effectiveness - Composite of All-cause Mortality and Stroke", "description": "Non-hierarchical composite endpoint of all-cause mortality and stroke at 1-year post-procedure", "timeFrame": "1 Year"}], "secondaryOutcomes": [{"measure": "New York Heart Association (NYHA) Functional Class - Change From Baseline", "description": "NYHA is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort.\n\nA decrease in NYHA class (negative value) shows patient improvement at 30 days.", "timeFrame": "30 Days"}, {"measure": "Kansas City Cardiomyopathy Questionnaire (KCCQ) - Change From Baseline", "description": "The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom, social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.\n\nAn increase in KCCQ score (positive value) shows patient improvement at 30 days.", "timeFrame": "30 days"}, {"measure": "Mitral Regurgitation - Change From Baseline", "description": "Echocardiographic assessment of the degree of mitral valve regurgitation\n\nNone=0, Trace=0.5, Mild or Mild-Moderate=1, Moderate=2, Moderate-Severe=3, and Severe=4.\n\nA decrease in MR (negative value) shows patient improvement at 30 days.", "timeFrame": "30 days"}, {"measure": "Pulmonary Artery Systolic Pressure - Change From Baseline", "description": "Echocardiographic assessment of pulmonary artery systolic pressure\n\nA decrease in pulmonary artery systolic pressure (negative value) shows patient improvement at 30 days.", "timeFrame": "30 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Failing surgically implanted bioprosthetic valve in the mitral position demonstrating \u2265 moderate stenosis and/or \u2265 moderate insufficiency.\n2. Surgical bioprosthetic valve with a true internal diameter (True ID) of 16.5 mm to 28.5 mm.\n3. NYHA Functional Class \u2265 II.\n4. Heart Team agrees the patient is intermediate risk (i.e. STS score of \u22653 and \\< 8).\n5. Heart Team agrees valve implantation will likely benefit the patient.\n6. The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) / Ethics Committee (EC) of the respective clinical site.\n\nExclusion Criteria:\n\n1. Index valve has \u2265 mild paravalvular regurgitation where the surgical bioprosthesis is not securely fixed in the native annulus or is not structurally intact as determined by transesophageal echocardiography (TEE).\n2. Surgical or transcatheter aortic valve placed so that extension into left ventricular outflow tract (LVOT) that may impinge on the mitral implant.\n3. Known residual mean gradient \\>10 mmHg at the end of the index procedure for implantation of the original surgical valve.\n4. Severe right ventricle (RV) dysfunction.\n5. Anatomical characteristics that would preclude safe access to the apex (transapical).\n6. Severe regurgitation or stenosis of any other valve.\n7. Severe lung disease (FEV1 \\< 50% predicted) or currently on home oxygen\n8. Severe pulmonary hypertension (e.g., PA systolic pressure \u2265 2/3 systemic pressure)\n9. Anatomical characteristics that would increase risk of LVOT obstruction (e.g., aortomitral angle, LVOT size, etc.).\n10. Evidence of an acute myocardial infarction \u2264 1 month (30 days) before enrollment.\n11. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days prior to the index procedure. Implantation of a permanent pacemaker (PPM) or implantable cardioverter defibrillator (ICD) is not considered an exclusion.\n12. Patients with planned concomitant surgical or transcatheter ablation for atrial fibrillation.\n13. Leukopenia (white blood count \\< 3000 cell/mL), anemia (hemoglobin \\< 9 g/dL), thrombocytopenia (blood platelet count \\< 50,000 cell/mL), history of bleeding diathesis or coagulopathy, or hypercoagulable states.\n14. Untreated clinically significant coronary artery disease requiring revascularization.\n15. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation, or mechanical heart assistance within 30 days of enrollment.\n16. Emergency intervention/surgical procedures within one month (30 days) prior to the procedure.\n17. Any planned surgical, percutaneous coronary, or peripheral procedure to be performed within the 30-day follow-up from the procedure.\n18. Hypertrophic cardiomyopathy with obstruction (HOCM).\n19. Left ventricular ejection fraction (LVEF) \\< 30%.\n20. Cardiac imaging evidence of intracardiac mass, thrombus, or vegetation.\n21. Inability to tolerate or condition precluding treatment with antithrombotic/anticoagulation therapy during or after the valve implant procedure.\n22. Absolute contraindications or allergy to iodinated contrast that cannot be adequately treated with premedication.\n23. Stroke or transient ischemic attack (TIA) within 90 days of enrollment.\n24. Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within 30 days of enrollment.\n25. Renal insufficiency (eGFR \\< 30 ml/min per the Cockcroft-Gault formula) and/or renal replacement therapy at the time of screening.\n26. Active bacterial endocarditis within 6 months (180 days) of the procedure.\n27. Patient refuses blood products.\n28. Estimated life expectancy \\< 24 months.\n29. Currently participating in an investigational drug or another device study. Note: Clinical trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.\n30. Positive urine or serum pregnancy test in female subjects of childbearing potential.", "healthyVolunteers": false, "sex": "ALL", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Mayra Guerrero, MD", "affiliation": "Mayo Clinic", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Chris S. Malaisrie, MD", "affiliation": "Northwestern University Feinberg School of Medicine", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Alan Zajarias, MD", "affiliation": "Washington University School of Medicine", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Emory University", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Northwestern University", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Northshore University Health System Research Institution", "city": "Evanston", "state": "Illinois", "zip": "60201", "country": "United States", "geoPoint": {"lat": 42.04114, "lon": -87.69006}}, {"facility": "Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Mayo Clinic", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "Barnes-Jewish Hospital/ Washington University", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "NYU Lagone Medical Center", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Providence Heart & Vascular Institution", "city": "Portland", "state": "Oregon", "zip": "97225", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "The Heart Hospital of Baylor Plano", "city": "Plano", "state": "Texas", "zip": "75093", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "The Prince Charles Hospital", "city": "Chermside", "state": "Queensland", "zip": "4032", "country": "Australia", "geoPoint": {"lat": -27.38472, "lon": 153.03062}}, {"facility": "Instituto do Cora\u00e7\u00e3o da Universidade de S\u00e3o Paulo", "city": "Cerqueira C\u00e9sar", "state": "S\u00e3o Paulo", "zip": "05403-900", "country": "Brazil", "geoPoint": {"lat": -23.03556, "lon": -49.16611}}, {"facility": "Instituto Dante Pazzanese de Cardiologia", "city": "Vila Mariana", "state": "S\u00e3o Paulo", "zip": "04012-909", "country": "Brazil", "geoPoint": {"lat": -23.58333, "lon": -46.63333}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Failing Mitral Transcatheter Valve", "description": "Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "53"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Failing Mitral Transcatheter Valve", "description": "Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "50"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.1", "spread": "9.66"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "27"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "23"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Asian", "measurements": [{"groupId": "BG000", "value": "3"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "4"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "31"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "7"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "5"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "34"}]}]}, {"title": "Brazil", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}]}]}, {"title": "Australia", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Safety and Effectiveness - Composite of All-cause Mortality and Stroke", "description": "Non-hierarchical composite endpoint of all-cause mortality and stroke at 1-year post-procedure", "populationDescription": "Valve implant population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "1 Year", "groups": [{"id": "OG000", "title": "Failing Mitral Transcatheter Valve", "description": "Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "New York Heart Association (NYHA) Functional Class - Change From Baseline", "description": "NYHA is a functional classification of heart failure based on how much a patient is limited during physical activity. The rating ranges from I - IV, with the lowest (I) as no limitations and the highest (IV) unable to carry on any physical activity without discomfort.\n\nA decrease in NYHA class (negative value) shows patient improvement at 30 days.", "populationDescription": "Valve implant population - 2 subjects did not complete the 30-day visit.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "30 Days", "groups": [{"id": "OG000", "title": "Failing Mitral Transcatheter Valve", "description": "Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.4", "spread": "0.73"}]}]}]}, {"type": "SECONDARY", "title": "Kansas City Cardiomyopathy Questionnaire (KCCQ) - Change From Baseline", "description": "The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom, social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.\n\nAn increase in KCCQ score (positive value) shows patient improvement at 30 days.", "populationDescription": "Valve implant population - 2 subjects did not complete the 30-day visit.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Failing Mitral Transcatheter Valve", "description": "Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31.0", "spread": "26.06"}]}]}]}, {"type": "SECONDARY", "title": "Mitral Regurgitation - Change From Baseline", "description": "Echocardiographic assessment of the degree of mitral valve regurgitation\n\nNone=0, Trace=0.5, Mild or Mild-Moderate=1, Moderate=2, Moderate-Severe=3, and Severe=4.\n\nA decrease in MR (negative value) shows patient improvement at 30 days.", "populationDescription": "Valve implant population - 4 subjects did not receive an echocardiogram at 30 days", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Failing Mitral Transcatheter Valve", "description": "Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.4", "spread": "1.48"}]}]}]}, {"type": "SECONDARY", "title": "Pulmonary Artery Systolic Pressure - Change From Baseline", "description": "Echocardiographic assessment of pulmonary artery systolic pressure\n\nA decrease in pulmonary artery systolic pressure (negative value) shows patient improvement at 30 days.", "populationDescription": "Valve implant population - 35 subjects had data at 30 days", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Failing Mitral Transcatheter Valve", "description": "Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.5", "spread": "14.64"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "1 Year", "eventGroups": [{"id": "EG000", "title": "Failing Mitral Transcatheter Valve", "description": "Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.", "deathsNumAffected": 0, "deathsNumAtRisk": 50, "seriousNumAffected": 21, "seriousNumAtRisk": 50, "otherNumAffected": 15, "otherNumAtRisk": 50}], "seriousEvents": [{"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Aortic valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 50}]}, {"term": "Atrial tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 50}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 50}]}, {"term": "Sinus node dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Ventricular fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Small intestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Prosthetic cardiac valve thrombosis", "organSystem": "General disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Myelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Suspected COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Vascular access site haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 50}]}, {"term": "Vascular pseudoaneurysm thrombosis", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Transvalvular pressure gradient increased", "organSystem": "Investigations", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Troponin increased", "organSystem": "Investigations", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Device deployment issue", "organSystem": "Product Issues", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Ecchymosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Arterial thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Haematoma", "organSystem": "Vascular disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}], "otherEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 50}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 50}]}, {"term": "Atrioventricular block first degree", "organSystem": "Cardiac disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 50}]}, {"term": "Prosthetic cardiac valve stenosis", "organSystem": "General disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 50}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 50}]}, {"term": "Anaemia postoperative", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 50}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "26.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 50}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": true}, "pointOfContact": {"title": "Director of Research", "organization": "Edwards Lifesciences", "email": "THV_ct.gov@edwards.com", "phone": "949-250-2500"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2020-05-08", "uploadDate": "2023-06-29T12:21", "filename": "Prot_SAP_000.pdf", "size": 1091297}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Canada"], "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2023-09-11", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000008944", "term": "Mitral Valve Insufficiency"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006349", "term": "Heart Valve Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "relevance": "LOW"}, {"id": "M11910", "name": "Mitral Valve Insufficiency", "asFound": "Mitral Valve Insufficiency", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M9437", "name": "Heart Valve Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}